From viral drift to tumor drift: why cancer immunotherapy needs B cells and dynamic adaptation
Current T-cell-based immunotherapies—chimeric antigen receptor T (CAR-T) cells, checkpoint inhibitors, and neoantigen vaccines—share a fundamental vulnerability: they target fixed antigens while tumors continuously evolve. Like influenza v…